慢性肾脏病成人衰弱状态与衰弱亚组中肾衰竭风险方程的验证
研究基于英国生物银行前瞻性队列中慢性肾脏病G3-5期成人,按衰弱状态验证四变量肾衰竭风险方程(KFRE)。衰弱者占35%,其5年肾衰竭风险被低估(观察/预期比1.70),将肌酐估算肾小球滤过率替换为胱抑素C估算值后校准改善(5年观察/预期比1.20),并需考虑竞争性死亡风险。
要点
- 四变量KFRE在衰弱个体中不能准确估计肾衰竭风险。
- 衰弱慢性肾脏病患者用胱抑素C估算肾小球滤过率替换肌酐可改善风险预测。
- 衰弱且KFRE预测风险较高者尤其需要考虑竞争性死亡风险。
核心结论
- KFRE低估慢性肾脏病合并衰弱个体的肾衰竭风险。
- 使用胱抑素C估算肾小球滤过率方程及考虑竞争性死亡风险可改善衰弱者的风险预测。
- 临床对衰弱个体使用KFRE计算时应考虑上述因素。
研究设计与样本
- 研究为前瞻性研究队列英国生物银行中慢性肾脏病G3-5期(估算肾小球滤过率<60 ml/min per 1.73 m2)成人。
- 衰弱通过改良衰弱表型和两种累积缺陷衰弱指数评估。
- 肾衰竭定义为长期透析或肾移植。
- 模型评估包括2年和5年的区分度、校准和整体拟合。
主要发现
- 一种或多种指标定义的衰弱患病率为35%(n=8533)。
- 衰弱组与非衰弱组的胱抑素C估算肾小球滤过率与肌酐估算肾小球滤过率之差分别为−15.8与−6.9 ml/min per 1.73 m2。
- KFRE区分度良好,在所有衰弱亚组和估算肾小球滤过率方程中受试者工作特征曲线下面积≥0.88。
- 衰弱个体5年肾衰竭被低估,观察/预期比为1.70(95%CI 1.55至1.85)。
- 将肌酐估算肾小球滤过率替换为胱抑素C估算肾小球滤过率后,5年观察/预期比为1.20(95%CI 1.05至1.35)。
临床怎么用
- 临床对衰弱个体使用KFRE计算时应考虑衰弱状态、胱抑素C估算肾小球滤过率及竞争性死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The four-variable kidney failure risk equation (KFRE) does not accurately estimate kidney failure risk in frail individuals. Prognostication of kidney failure is improved in frail individuals with CKD by replacing eGFR creatinine with cystatin C-based eGFR in the KFRE model. Consideration of competing mortality risk is particularly important in those with frailty and higher KFRE risk predictions. BACKGROUND: Frailty is common among adults with CKD, and its presence can influence clinical outcomes, such as advancing CKD and mortality. Clinical guidelines recommend the use of the kidney failure risk equation (KFRE) to guide management of CKD. Our aim was to validate KFRE by frailty status and assess whether model performance could be improved by using cystatin C-based eGFR equations and to assess the effect of accounting for competing mortality risk. METHODS: We studied adults from the prospective research cohort UK Biobank with CKD G3–5 (eGFR <60 ml/min per 1.73 m2) by any of the three CKD Epidemiology Collaboration consortium eGFR equations: eGFR creatinine (eGFRcr), eGFR cystatin C (eGFRcys), and eGFR cystatin C-cystatin. Frailty was assessed by a modified frailty phenotype and two cumulative deficit frailty indices. Kidney failure was defined as long-term dialysis or kidney transplantation. Model assessment included discrimination, calibration, and overall fit at 2 and 5 years. RESULTS: The prevalence of frailty by one or more measures was 35% (n=8533). Those classed as frail had a higher discrepancy between eGFRcys and eGFRcr compared with the nonfrail group (−15.8 versus −6.9 ml/min per 1.73 m2). Discrimination of KFRE was good (area under the receiver operating characteristic curve ≥0.88 across all frailty subgroups and eGFR equations). Kidney failure at 5 years was underestimated in individuals with frailty (observed/expected ratio, 1.70; 95% confidence interval, 1.55 to 1.85). Calibration-in-the-large improved when eGFRcr was replaced by eGFRcys (5-year observed/expected ratio, 1.20; 95% confidence interval, 1.05 to 1.35). Overestimation of kidney failure risk in analyses that do not account for competing mortality risk, compared with those that do, was most apparent in the frailty group and the higher KFRE predicted risk groups. CONCLUSIONS: KFRE underestimates kidney failure risk of individuals with CKD and frailty. Risk prediction improved for those with frailty when cystatin C-based eGFR equations are used and when analyses account for competing risk of mortality. These factors should be considered when KFRE calculation is used in clinical practice in individuals with frailty.
引用
- Walker H, Carrero JJ, Sullivan MK, et al. Frailty in Adults with CKD and Validation of the Kidney Failure Risk Equation in Frailty Subgroups. Clin J Am Soc Nephrol. 2025. PMID: 40397539. doi:10.2215/CJN.0000000739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。